This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| GRN | |
|---|---|
| Name | GRN |
| Other symbols | PC-cell-derived growth factor, PCDGF, progranulin |
| Chromosomal location | 17q21.31 |
| Organism | Human |
GRN GRN encodes progranulin, a secreted glycoprotein implicated in neuronal survival, inflammation, and tissue repair. First characterized in studies linking growth factors to oncogenesis, GRN has since been connected to neurodegenerative syndromes, wound healing, and cancer biology. Research on GRN spans genetics, cell biology, neuropathology, and translational therapeutics, drawing interest from investigators at institutions such as Massachusetts General Hospital, St. Jude Children's Research Hospital, and universities including Harvard University and University of Cambridge.
GRN was cloned in the context of growth factor research alongside studies involving Epidermal Growth Factor, Transforming Growth Factor beta, and Fibroblast Growth Factor. The gene maps to chromosome 17q21.31 and produces a precursor progranulin protein cleaved into granulins; these peptides were described in parallel with work on Porcine Elastase and serine proteases. Progranulin became notable when geneticists linked loss-of-function variants to frontotemporal lobar degeneration cases investigated at centers like Rush University Medical Center and University College London. Parallel oncology studies associated GRN overexpression with tumor progression in cohorts from MD Anderson Cancer Center and Dana-Farber Cancer Institute.
GRN comprises multiple exons and encodes a 593–amino-acid precursor subject to post-translational glycosylation investigated by laboratories at Yale University and Stanford University. Pathogenic heterozygous null variants, including nonsense and frameshift mutations, were reported in pedigrees examined by teams at University of California, San Francisco and Washington University in St. Louis. Population genetics surveys such as those from the 1000 Genomes Project and Exome Aggregation Consortium catalog variant frequencies and inform penetrance estimations used by clinical groups including Mayo Clinic and Johns Hopkins University. GRN expression is regulated transcriptionally by factors studied in laboratories at Max Planck Society and epigenetically in cohorts characterized by Broad Institute researchers. Proteolytic processing into granulins is mediated by proteases such as elastase and matrix metalloproteinases characterized in studies at Scripps Research and Cold Spring Harbor Laboratory.
Heterozygous loss-of-function mutations in GRN are a major cause of frontotemporal dementia studied extensively at University of Toronto and Karolinska Institutet, with clinicopathologic correlations reported from registries at Memory and Aging Center (UCSF). GRN haploinsufficiency produces TDP-43 proteinopathy phenotypes described in cohorts from Boston University and University of California, San Diego. Reduced progranulin levels have been associated with corticobasal syndrome and primary progressive aphasia in case series from Mayo Clinic and King's College London. Conversely, GRN overexpression correlates with poor prognosis in malignancies investigated at Memorial Sloan Kettering Cancer Center and Cleveland Clinic, including breast, ovarian, and glioblastoma cohorts assessed by groups at University of Pennsylvania and University of Michigan. Inflammatory disorders and lysosomal storage investigations by teams at National Institutes of Health and Institut Pasteur implicate progranulin in rheumatoid arthritis and neuronal ceroid lipofuscinosis phenotypes.
Progranulin modulates neuronal survival pathways identified in mechanistic studies at Columbia University and regulates microglial activation described by investigators at University of Cambridge and Imperial College London. GRN influences lysosomal biogenesis through interactions delineated with proteins studied at Rockefeller University and affects autophagy pathways explored at Karolinska Institutet. At the cellular signaling level, progranulin engages receptors and downstream cascades examined in models from University of California, Berkeley and University of Oxford, intersecting with pathways involving Sortilin and TNF receptor family members characterized in proteomic studies at European Molecular Biology Laboratory. Granulin peptides exert distinct effects on cell proliferation and inflammation in experiments performed at University of Chicago and University of Edinburgh.
Genetic linkage and sequencing studies implicating GRN employed approaches developed at Wellcome Trust Sanger Institute and bioinformatics pipelines from the European Bioinformatics Institute. Cellular assays use overexpression, siRNA knockdown, and CRISPR/Cas9 editing as implemented in core facilities at Broad Institute and Cold Spring Harbor Laboratory. Animal models include Grn-knockout and transgenic mice generated and phenotyped at Jackson Laboratory and behavioral cohorts assessed at McGill University. Induced pluripotent stem cell models derived from patient fibroblasts have been established by consortia including Stanford University and University College London to study neuronal and microglial phenotypes. Imaging and biomarker investigations leverage platforms from National Institute on Aging and proteomics cores at EMBL-EBI.
Therapeutic strategies targeting GRN biology include small molecules that increase progranulin expression, antisense oligonucleotides, and receptor modulators pursued by biotech firms and academic partnerships with groups such as Biogen, Roche, and startups from Cambridge, Massachusetts incubators. Clinical trials overseen by centers like Mayo Clinic and Massachusetts General Hospital evaluate progranulin-elevating agents and gene therapy vectors using adeno-associated virus platforms pioneered at University of Pennsylvania and Children's Hospital of Philadelphia. Monoclonal antibodies and lysosomal enhancers are under preclinical development in collaborations between Novartis and academic labs at University of Zurich. Biomarker-guided trials employ CSF and plasma progranulin assays standardized in studies from Emory University and University of Sydney to stratify participants and measure pharmacodynamic effects.
Category:Human genes